• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Universal Donor Red Blood Cells Can Be Genetically Engineered Using CRISPR Gene Editing

May 2, 2018

Alloimmunization commonly affects 2-5% of all transfusion recipients and approximately 30% of chronically transfused patients with sickle-cell disease. Since ABO (Bombay phenotype), Rh, Kell, Duffy, and GPB blood group systems are prevalent antigens at the root of many alloimmunization reactions, researchers in the United Kingdom used CRISPR-Cas9 gene editing to create red blood cells void of these antigens.  CRISPR (clustered regularly interspaced short palindromic repeats)-Cas9 is derived from bacteria, which uses the system as a primitive immune system to recognize and cleave short fragments of invading viral DNA.  Researchers took advantage of CRISPR’s ability to recognize and cut any strand of DNA and knocked-out the genes for ABO, Rh, Kell, Duffy and antigens on glycophorin B in the human erythroblast cell line BEL-A.  These cells differentiated into normally shaped reticulocytes void of these five antigens and could potentially be used as universal donor RBCs.  This proof of principle study is encouraging that other antigens could be targeted to help meet the transfusion needs of patients who need complicated antigen matches.

Reference:

  1. Hawksworth J, Satchwell TJ, Meinders M, Daniels DE, et al. Enhancement of red blood cell transfusion compatibility using CRISPR-mediated erythroblast gene editing. EMBO Molecular Medicine 2018

Filed Under

  • Blood Donation
  • News
  • RBC Transfusion

Recommended

  • Evaluation of PrEP/PEP Deferrals and U.S. House of Representatives Question MSM Deferral Policy for Blood Donors

  • Tranexamic Acid Treatment Does Not Reduce Hematoma Growth in Patients with Intracerebral Hemorrhage

  • SARS-CoV-2 Seropositivity of U.S. Blood Donors Prior to Availability of Vaccines

Show Comments

Reader Interactions

Comments

  1. Dr. Zacchaeus Olofin says

    May 8, 2018 at 10:03 am

    Wao! This is a good innovation/ discovery. This will give hope to those who require recurrent transfusion and their religious belief does not support it.

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Directed Blood Donations Should be Limited

  • Babesia Infection Reduces Red Cell Deformability

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley